More specifically, if patients with CNS WHO grade 4 glioma do not have CDKN2A deletion, they have longer PFS and OS than those with a CDKN2A deletion, regardless of the presence of IDH mutation. This evidence concerns the gene CDKN2A and central nervous system cancer.